title: JAK Inhibitors and other Novel Agents in Myeloproliferative Neoplasms: Are We Hitting the Target?
abstract: The discovery of somatic mutations in the JAK-STAT signaling pathway was a major breakthrough in our understanding of the molecular pathogenesis of the myeloproliferative neoplasms (MPNs) polycythemia vera, essential thrombocytosis, and primary myelofibrosis. This finding led to the development of small molecule inhibitors targeting Janus kinase (JAK) 2 and other JAK family members. Currently, there are a number of research and clinical trials ongoing with JAK inhibitors. While the appeal of inhibiting JAK2 is clear, studies to date suggest that JAK2 inhibitor monotherapy might not be sufficient to cause reductions in disease allele burden in MPN patients. There is compelling evidence that JAK inhibitors are improving symptoms and therefore quality of life for patients. It will be important to investigate the efficacy of JAK inhibitors in preclinical and clinical studies to better understand their effects, while at the same time pursuing alternative therapies which might offer benefit to MPN patients alone and in combination with JAK inhibitors.
authors.affiliation: Human Oncology and Pathogenesis Program and Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, USA.
authors.forename: Nicole
authors.initials: N
authors.lastname: Kucine
authors.forename: Ross L
authors.initials: RL
authors.lastname: Levine
keywords: JAK inhibitor; JAK kinases; essential thrombocytosis; myelofibrosis; myeloproliferative disorder; polycythemia vera
references.citation: Lancet. 2005 Mar 19-25;365(9464):1054-61
references.pmid: 15781101
references.citation: Blood. 2008 Sep 15;112(6):2190-8
references.pmid: 18779404
references.citation: N Engl J Med. 2010 Sep 16;363(12):1117-27
references.pmid: 20843246
references.citation: Lancet. 1978 Dec 9;2(8102):1219-22
references.pmid: 82733
references.citation: Cell Commun Signal. 2009 Jul 16;7:17
references.pmid: 19607667
references.citation: J Clin Oncol. 2011 Mar 1;29(7):789-96
references.pmid: 21220608
references.citation: Blood. 2008 Oct 15;112(8):3065-72
references.pmid: 18650451
references.citation: J Biol Chem. 2006 Jan 27;281(4):1876-84
references.pmid: 16280321
references.citation: Leukemia. 2008 Sep;22(9):1790-2
references.pmid: 18354492
references.citation: Leukemia. 2008 Apr;22(4):740-7
references.pmid: 18079739
references.citation: Am J Hematol. 2010 Sep;85(9):675-86
references.pmid: 20652971
references.citation: Blood. 2008 Feb 1;111(3):1686-9
references.pmid: 17984312
references.citation: Hematology. 2009 Feb;14(1):11-5
references.pmid: 19154659
references.citation: Blood. 2006 Jan 1;107(1):176-83
references.pmid: 16174768
references.citation: Blood. 2010 Feb 11;115(6):1131-6
references.pmid: 20008298
references.citation: PLoS Med. 2006 Jul;3(7):e270
references.pmid: 16834459
references.citation: Cancer Cell. 2009 Dec 8;16(6):487-97
references.pmid: 19962667
references.citation: Nature. 2005 Apr 28;434(7037):1144-8
references.pmid: 15793561
references.citation: Blood. 2008 Jun 15;111(12):5663-71
references.pmid: 17984313
references.citation: J Clin Invest. 2010 Oct;120(10):3578-93
references.pmid: 20852385
references.citation: Physiol Res. 2010;59(2):165-175
references.pmid: 19537936
references.citation: Br J Haematol. 1998 Dec;103(3):772-7
references.pmid: 9858229
references.citation: Cancer Cell. 2005 Apr;7(4):387-97
references.pmid: 15837627
references.citation: Cancer Cell. 2008 Apr;13(4):311-20
references.pmid: 18394554
references.citation: Blood. 2003 Dec 1;102(12):3912-8
references.pmid: 12920019
references.citation: Blood. 2010 Jun 24;115(25):5232-40
references.pmid: 20385788
references.citation: N Engl J Med. 2005 Jul 7;353(1):33-45
references.pmid: 16000354
references.citation: Blood. 2006 Nov 15;108(10):3472-6
references.pmid: 16868251
references.citation: N Engl J Med. 2010 Sep 16;363(12):1189-90
references.pmid: 20843259
references.citation: N Engl J Med. 2007 Feb 1;356(5):459-68
references.pmid: 17267906
references.citation: Leukemia. 2011 Feb;25(2):218-25
references.pmid: 21079613
references.citation: N Engl J Med. 2001 Apr 5;344(14):1038-42
references.pmid: 11287973
references.citation: J Clin Oncol. 2005 Apr 1;23(10):2224-32
references.pmid: 15710945
references.citation: Minerva Dermatol. 1967 Mar;42(3):83-5
references.pmid: 4862902
references.citation: Am J Hematol. 2010 Sep;85(9):715-6
references.pmid: 20661915
references.citation: Cancer Cell. 2010 Jun 15;17(6):584-96
references.pmid: 20541703
references.citation: Leukemia. 1999 Feb;13(2):150-4
references.pmid: 10025886
references.citation: Blood. 2010 Apr 15;115(15):3109-17
references.pmid: 20130243
references.citation: J Clin Oncol. 2009 Nov 10;27(32):5418-24
references.pmid: 19826111
references.citation: Leukemia. 2009 Aug;23(8):1441-5
references.pmid: 19295546
references.citation: Blood. 1951 Apr;6(4):372-5
references.pmid: 14820991
references.citation: N Engl J Med. 2005 Apr 28;352(17):1779-90
references.pmid: 15858187